Skip to main content

Table 4 Survival analysis was performed by the Kaplan-Meier method

From: CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study

Variables N Means for survival time (month) Survival time (month, 95% CI) P value
CILP2 expression Low 304 83.770 74.181 93.359 0.003
High 305 70.805 61.802 79.807
Total 609 77.193 70.583 83.803
Gender Male 329 74.017 64.871 83.163 0.941
Female 280 80.242 70.918 89.566
Total 609 77.193 70.583 83.803
Age ≤ 68 324 86.777 77.219 96.334 < 0.0001
> 68 285 68.173 59.326 77.021
Total 609 77.193 70.583 83.803
T stage T1/2 126 97.409 81.150 113.667 0.003
T3/4 481 74.489 67.519 81.460
Total 607 77.572 70.950 84.194
N stage N0 348 88.348 79.810 96.887 < 0.0001
N1/2/3 257 63.017 53.234 72.799
Total 605 77.530 70.908 84.152
M stage M0 450 87.130 79.689 94.571 < 0.0001
M1 86 37.131 29.468 44.794
Total 536 78.778 71.809 85.747
Clinical stage Stage I/II 330 89.089 80.335 97.843 < 0.0001
Stage III/IV 262 64.632 54.851 74.413
Total 592 78.325 71.646 85.005
  1. P value < 0.05 was considered statistically significant (in bold). T tumor, N regional lymph node, M metastasis